相关实验视频

Updated: Jul 17, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

卡尔-T细胞双重向CD123和NKG2DLs来根除AML细胞,并选择性地向免疫抑制细胞

Xin Jin^1,2,3, Danni Xie⁴, Rui Sun¹

¹School of Medicine, Nankai University, Tianjin, China.

|August 30, 2023

概括

新的CAR-T疗法针对急性髓性白血病 (AML) 细胞和免疫抑制细胞. 这种双重定位的方法克服了AML.

科学领域:

免疫治疗是一种免疫疗法.
血液瘤学血液瘤学
细胞疗法细胞疗法

背景情况:

化学抗原受体 (CAR) -T细胞疗法在急性髓性白血病 (AML) 中显示出有限的疗效,这是由于免疫抑制性瘤微环境.
甲型AML细胞异质性和免疫抑制细胞的存在,如髓质衍生抑制细胞 (M-MDSC) 和M2巨细胞,阻碍了CAR-T细胞的功能.
针对单个抗原的现有CAR-T策略不足以根除异质AML种群,导致复发.

研究的目的:

开发一种新型的双重向的CAR-T细胞疗法来治疗AML.
为了克服AML的免疫抑制微环境和向瘤细胞异质性.
为了设计CAR-T细胞具有可控消除的安全开关.

主要方法:

开发针对CD123和NKG2D配体 (NKG2DLs) 的双重向的123NLCAR-T细胞.
结构优化CAR构造以提高效率.
纳入一个标记/自杀基因 (RQR8) 进行有条件的CAR-T细胞消除.

主要成果:

123NL CAR-T细胞在根除AML细胞方面表现出有效性.
改造的CAR-T细胞有选择地向并消除免疫抑制的M-MDSC和M2细胞.
自杀基因RQR8使Rituximab通过123NL CAR-T细胞的消除成为可能,提供了一个安全机制.

结论:

双重向的123NL CAR-T细胞提供了一个有希望的策略,以克服AML治疗的挑战.
这种方法有效地针对瘤微环境中的恶性和免疫抑制细胞.
集成的安全开关增强了CAR-T细胞治疗在AML中的治疗潜力和控制.

关键词:

在AML,AML就是AML.在CART-T中,我们可以使用CAR-T.在CD123中使用CD123.在NKG2DL中,NKG2DL是指NKG2DL.免疫疗法免疫疗法

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...